Director's Dealings

Cellular Goods PLC
12 January 2024
 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014, as retained as part of the law of England and Wales. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

12 January 2024

Cellular Goods PLC

("Cellular Goods" or "The Company")

Director's Dealings

 

Cellular Goods (LSE: CBX), a UK-based company pioneering the use of lab-based and biosynthetic production methods for wellness and sustainability solutions, announces that Michael Edwards (Executive Director of Cellular Goods) has purchased a total of 1,400,000 ordinary shares in the Company ("Ordinary Shares"), the details of which are set out in the notification below. Following this purchase, Michael Edwards holds a total of 9,400,000 Ordinary Shares, representing 1.56 per cent of the Company's issued share capital.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Michael Edwards

2.

Reason for the Notification

a)

Position/status

Executive Director

b)

Initial notification / Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cellular Goods PLC

b)

LEI

213800IXPX4Z2MKX2U28

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary shares


Identification Code

GB00BK964W87

b)

Nature of the transaction

Purchase of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

0.707 pence per Ordinary Share

1,400,000 Ordinary Shares

d)

Aggregated information:

· Aggregated volume

· Price

 

1,400,000 Ordinary Shares

0.707 pence per Ordinary Share

e)

Date of the transaction

11 January 2024

f)

Place of the Transaction

London Stock Exchange

 

 

 

For further information please contact:

Cellular Goods


Michael Edwards

Director

via FSCF +44 7572 873 300

First Sentinel Corporate Finance (FSCF)


Investor Relations

Rebecca Noonan

IR@cellular-goods.com

Media Relations

Rebecca Noonan

Media@cellular-goods.com

Corporate Broker & Advisor

Brian Stockbridge

 

+44 7572 873 300

 

 

+44 7572 873 300

 

 

+44 7858 888 007

Novum Securities

 

Corporate Broker

Colin Rowbury

Jon Belliss

 

 

+44 207 399 9427 

 

 

About Cellular Goods PLC:

Cellular Goods is pioneering the use of lab-based and biosynthetic production methods for wellness and sustainability solutions. The Company launched with a focus on efficacy led and science-backed products utilising biosynthetics, and now employs its expertise across two verticals: premium next-generation cannabinoid skincare products, and carbon sequestration-as-a-service through its wholly owned business division, King Tide Carbon, which utilises biosynthetic algae and seaweed to provide scalable carbon removal. The Company is incorporated in the UK and listed on the Main Market of the London Stock Exchange. For more information, visit www.cellular-goods.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Cel AI (CLAI)
UK 100

Latest directors dealings